Biological PCR Technology Market to Extend US$ 28.93 Bn by 2034

Biological PCR Technology Market Size, Growth, and Future Insights

The global biological PCR technology market was estimated at US$ 13.69 billion in 2023 and is projected to grow to US$ 28.93 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.04% from 2024 to 2034. The rising incidence of infectious diseases, the need for diagnosis and treatment, and advancements in medical technologies including genomics and proteomics research are leading to the expansion of the biological PCR technology market globally.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

Polymerase chain reaction is one of the widely used DNA amplification methods which uses different reaction components like template DNA, four nucleotides namely dATP, dGTP, dCTP, dTTP, and DNA polymerase enzyme that synthesizes the DNA. The reaction cycle is performed in PCR instruments by setting up ideal temperatures for each of the three reaction steps including denaturation, annealing, and extension. This technique is also performed for mutation detection, DNA fingerprinting assay, etc.

According to the India Bioeconomy Report 2023, the diagnostic market in India showed remarkable growth in 2022 and India conducted approximately 600 to 700 million diagnostic tests annually with a daily average of 2 million tests. About 1390 new biotechnology startups joined the ecosystem in 2022 and there was a wave of innovation with the launch of more than 50 cutting-edge products in the healthcare and life sciences domain. The enzymes used in PCR technology enhance efficiency and play vital roles in sustainable bioindustrial practices.

Biological PCR Technology Market Trends

• In January 2024, the U.S. National Science Foundation awarded funding to a project entitled ‘Eager Sentinels: The PCR-free Biosensor for a Fast, Simple, and Sensitive Detection of RNA’ with an award amount of $249,997.00 to the University of Louisiana at Lafayette.
• The UK Innovation Strategy of the government aims to make the UK a global hub for innovation by 2035 by increasing annual public investment in R&D to a record £22 billion.
• The Strategic Plan 2025-2029 of the National Institute of Environmental Health Sciences entitled ‘Health at the Intersection of People and their Environments’ reflects a framework committed to research areas of emphasis, crosscutting themes, capacity and infrastructure, and scientific management and stewardship.

With the rising prevalence of infectious diseases, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (USFDA) facilitated the approval processes of PCR testing devices along with other medical technologies. In the COVID-19 pandemic, the widespread adoption of PCR machines, RT-PCR kits, PCR reagents, and many other required medical devices led the biological PCR technology market noticeably. Dr. Rajesh Gokhale, Secretary of the Department of Biotechnology (DBT) and Chairman of BIRAC reported their vision to help India’s bioeconomy reach $300 billion by 2030 and account for 5 to 6% share of India’s GDP. The U.S. National Science Foundation awarded funding to a project for January 2024-January 2025 which aims to design a rapid, ultrasensitive, and adaptable PCR-free biosensing platform for viral RNA detection.  

Market Challenge

A high cost of maintenance is required for the PCR instruments known as thermal cyclers and mainly healthcare facilities in developing countries and small laboratories can face tough financial competition. Many institutions fall behind due to the inability of high capital investment required for high-grade PCR machines to be implemented for routine diagnosis and research. Researchers will be unable to perform infectious disease detection and molecular evaluation. The costs required for consumables, personal training, and technical support can present a financial burden in front of the laboratories for the incorporation of standard PCR, qPCR, and RT-PCR machines.

Regional Insights

Asia Pacific is the fastest-growing region in the biological PCR technology market due to improved public access to modern healthcare facilities and advancements in genomics research in countries like China, Germany, Japan, etc. Japan leads the market by holding a well-established healthcare infrastructure and several cancer research activities are fueling the market’s growth. In India, there is a presence of a large number of the patient population and the government is supporting healthcare expenditure. In Australia, strong government measures are enabling the adoption of advanced PCR technologies. In South Korea, improved medical tourism and the rising prevalence of chronic diseases are propelling the market’s growth. An increased shift towards personalized medicines is also boosting the market’s portfolio. The growing number of hospitals and diagnostic laboratories and continuous improvements in PCR technology-based products are driving the market’s progress in the Asia Pacific region. The key industrial players are increasingly launching new innovative products with the approvals for the global utilization of medical products.

The biotechnology industry witnessed significant growth in private equity (PE) and venture capital (VC) investments in 2022 with a record-breaking $938.8 million (19%) growth in private equity investments than in 2021.

The biopharma therapeutics segment holds an annual value of $16.8 billion which proves its strong presence in the great biopharmaceutical industry. This sector contributes approximately $46.03 million daily and $1.4 billion monthly in the bioeconomy shaping the industry.

North America dominated the biological PCR technology market in 2023 due to the supportive government initiatives for genomics research in Canada and the United States. In Europe, countries like Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe are propelling the market’s expansion. The presence of well-established pharmaceutical and R&D industries is contributing to the rising investments in research and development of life Science fields. There are increasing investments in R&D infrastructural development in France and Germany. The healthcare professionals and clinicians are accepting genome-based diagnosis and treatment strategies and government policies are supportive with high healthcare expenditure. The government funding opportunities for life science research and pharmaceutical drug development also boost the market’s growth remarkably. There is a growing focus of scientists on genomics and proteomics research and some countries offer favorable trade agreements to support the import of medical products. These factors improve accessibility to PCR instruments not only in the North American region but also in other regions like Europe, and Latin America including Mexico and Brazil, and the Middle East and Africa.

• In March 2023, the U.S. Department of Health and Human Services reported the U.S. Food and Drug Administration (FDA) Clearance of Simplexa COVID-19 and Flu A/B Direct which is a real-time RT-PCR system or a molecular diagnostic test for the direct amplification and detection of SARS-CoV-2 (COVID-19 Virus), influenza A, and influenza B RNA, from nasopharyngeal swab specimens that have not undergone nucleic acid extraction.
• In May 2024, the Mexico International Health Regulations (IHR) National Focal Point (NFP) reported the first laboratory-confirmed human case of infection with an avian influenza A (H5N2) virus. The World Health Organization conducts an assessment of its risks to the public health.

Segmental Insights

Product Type Insights

Reagents and consumables led the biological PCR technology market as the ideal chemicals required for DNA amplification including primers, nucleotides, DNA polymerase enzyme, reaction buffer, etc. The consumables include single-use PCR tubes, pipette tips, plates, etc. With the high demand, multiple PCR tests can run at a time. 

End User Insights

The diagnostic laboratories segment dominated the biological PCR technology market in 2023 due to their crucial role in the diagnosis of infectious diseases such as HIV, COVID-19, hepatitis, genetic diseases, and cancer cases. PCR is the widely used technique for the detection of infections caused by viruses, bacteria, or parasites due to its accuracy and high precision of diagnosis. Molecular diagnostic laboratories are greatly adopting PCR technologies and PCR machines to enhance performance accuracy.

Recent Developments

• In April 2023, Promega Corporation announced awarding $15,000 grants to researchers using real-time quantitative PCR (qPCR). Promega will also award researchers with VIP technical support and personalized training.
• In November 2023, F. Hoffman --La Roche Ltd introduced a new next-generation qPCR system named Light Cycler PRO System to enhance molecular diagnostics efficiency in fulfilling clinical needs.
• In April 2023, Gabriela Saldanha, the product marketing manager of Promega Corporation, said that the grant awarded by Promega will help researchers leverage the most powerful molecular biology techniques called qPCR and the company is excited to connect with young researchers and students to assist them with qPCR ways in their projects all over the world.
• Rick Woychik, Ph.D., the Director of the National Institute of Environmental Health Sciences (NIEHS) invited people to make a bold prediction about the impact of the NIEHS strategic plan 2025-2029 on human health around the world.

Top Companies in the Biological PCR Technology Market

• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN
• ABBOTT
• Takara Bio Inc.
• Merck KGAA
• Bioneer Corporation
• ILLUMINA Inc.
• Promega Corporation
• Eppendorf S

Segments Covered

By Product Type

• Reagents
• Consumables

By End User

• Diagnostic Laboratories
• Molecular Testing Laboratories

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait